Tags : pembrolizumab

Clinical Trials

Linnaeus Reports First Patients Dosing with LNS8801 + Keytruda (pembrolizumab)

Shots: The first patient has been dosed in P-l/ll adaptive-design study assessing the safety, tolerability, pharmacokinetics, and antitumor activity of LNS8801+ Keytruda (pembrolizumab) in patients who had previous clinical benefit from immune checkpoint inhibitors and then subsequently progressed The initiation of the study follows the identification of the RP2D in the ongoing study of LNS8801. […]Read More